NCT04279743 · UNKNOWN

Fatty Acid Metabolism in Carriers of Apolipoprotein E Epsilon 4 Allele: Determining the Blood-to-brain Link

This trial is testing whether two different forms of omega-3 supplements — one packaged as phospholipids, one as triglycerides — deliver DHA (the brain-healthy fat in fish) to the brain differently, and whether APOE4 carriers absorb and transport DHA less efficiently than non-carriers. It is a mechanistic study, not a treatment trial — meaning researchers are trying to understand a biological process, not prove a therapy works.

Eligibility criteria

Inclusion Criteria:
- Men and women aged between 30-50 years old.
Exclusion Criteria:
* Tobacco use,
* Malnutrition (assessed from blood albumin, hemoglobin and lipids),
* Diabetes,
* Participants taking an EPA+DHA supplement or consuming more than 2 fish meals per week,
* Uncontrolled thyroid, renal and endocrine disorder disease,
* Chronic immune condition or inflammation (CRP > 10 mg/l, white cell count),
* Cancer,
* Recent major surgery or cardiac event,
* Pregnant or lactating women,
* Pre-menopause or menopause,
* Dementia,
* Ongoing or past severe drug or alcohol abuse,
* Psychiatric difficulties or major depression
* Ongoing or past intensive physical training.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2020-05-07

View full record on ClinicalTrials.gov

All APOE4 clinical trials